ADC manufacturing

Products

Information

Sterling’s dedicated bioconjugation facility, located in Deeside, Wales, can handle a variety of batch sizes to support cGMP clinical and preclinical manufacture of antibody drug conjugates (ADCs) and bioconjugates. Through our integrated global network, we are also capable of manufacturing linker payloads at our Wisconsin, US and North Carolina, US facilities. Our antibody drug conjugation (ADC) manufacturing team possesses experience in GMP production for biotechnology and biologics, supported by experts from across our global contract development and manufacturing organisation.
Sterling Pharma SolutionsSterling Pharma Solutions is a global contract development and manufacturing organisation (CDMO) with more than 50 years' experience in providing small molecule API, as well as Antibody Drug Conjugate (ADC), development and manufacturing services to the pharmaceutical industry, specialising in handling challenging chemistries. Sterling has five facilities employing 1,350+ people: its HQ in Cramlington, UK and a facility in Ringaskiddy, Ireland; two sites in the US, in North Carolina and Wisconsin; and a dedicated bioconjugation facility in Deeside, Wales.

Log in

See all the content and easy-to-use features by logging in or registering!